Hemab Therapeutics Holdings Inc COAG
$44.41 $0.04 (0.09%) 1D
Last Updated: Sep 04, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Hemab Therapeutics Holdings Inc Stock Halal?
Shariah Compliance Analysis of COAG Stock
United States Health Care Mid Cap No. As of September 2026, Hemab Therapeutics Holdings Inc (COAG) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Hemab Therapeutics Holdings Inc does not pass Musaffa's business and financial screening criteria.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 72 full-time employees. The company went IPO on 2026-05-01. The firm is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. The company is also advancing multiple preclinical and discovery-stage assets.
COAG Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Hemab Therapeutics Holdings Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Hemab Therapeutics Holdings Inc (COAG) Chart
Financial Metrics & Statements of Hemab Therapeutics Holdings Inc (COAG)
FAQ's for Hemab Therapeutics Holdings Inc (COAG)
- As of September 2026, Hemab Therapeutics Holdings Inc COAG is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hemab Therapeutics Holdings Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Hemab Therapeutics Holdings Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Hemab Therapeutics Holdings Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Hemab Therapeutics Holdings Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Hemab Therapeutics Holdings Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Hemab Therapeutics Holdings Inc (COAG)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
